Here’s What Happened at PropThink This Week
Long Ideas - Cadence (CADX) was a compelling buy last year as the sales ramp for its IV acetaminophen formulation began to improve. A position since Mr. King … Continue Reading
Read nowSearch Results for endo health
Ohr Pharma is Under-The-Radar with Upcoming Catalysts; Potential For Significant Payoff
Long Ideas - Wet macular degeneration is a chronic eye disease that causes vision loss and generally occurs later in life (50+), as blood vessels leak fluid or … Continue Reading
Read nowDon’t Miss the Forest for the Trees, Sarepta is a Top Biotech Investment
Long Ideas - Sarepta Therapeutics (SRPT) has become a bit of a lightning rod, with the company’s shares trading near the middle of their 52-week range (from $3.30 … Continue Reading
Read nowThe Music Stops For ResMed: Significant Potential Downside, and Management’s Already Grabbed A Seat
Most Popular - Shares of ResMed Inc. (RMD) have finally found their top, peaking at $48.37 in late January before dropping to the $43 level. But the downslide … Continue Reading
Read nowSangamo BioSciences: A Potentially Revolutionary 2013
Long Ideas - In medicine, there are certain watershed moments that become an enduring part of medical history, such as the discovery of penicillin, or the eradication of … Continue Reading
Read nowENDP’s Lower Guidance Not Much Of A Surprise; Negative Sentiment Remains An Opportunity
Long Ideas - Endo Pharmaceuticals (NASDAQ:ENDP) reported 3Q 2012 adjusted EPS of $1.28, ahead of the Consensus estimate of $1.26. However, revenues for the period came in at … Continue Reading
Read nowENDP’s Deep Discount Won’t Last; Upside Scenarios Are Icing On The Cake
Long Ideas - Shares of Endo Pharmaceuticals (NASDAQ:ENDP) are trading at a deep discount to other pharmaceutical companies, with the last dip in price coming on the heels … Continue Reading
Read now